bjmu.edu.cn or Professor Liwei Lu, Department of Pathology and Center for Infection and Immunology, The University of Hong Kong, China; liweilu@hku.hk Objective Regulatory T cells (Tregs) with the ...

肝细胞癌（HCC）是全球常见的恶性肿瘤，且大部分患者确诊时已处于中晚期，预后不佳[1]。尽管靶向和免疫治疗的快速发展为晚期 HCC 患者带来了新的希望，但效果仍不尽如人意，难以满足临床需求[2]。双免疫联合治疗作为临床研究的热点，近年来在晚期 HCC ...

撰文丨王聪编辑丨王多鱼排版丨水成文免疫疗法为癌症患者带来了巨大的希望，但癌症免疫疗法的总体效率仍然有限，许多癌症患者对癌症免疫疗法无反应。肿瘤诱导的免疫抑制是有效的肿瘤免疫治疗的关键障碍之一。肿瘤细胞能够利用不同的机制来营造独特的免疫抑制性肿瘤微环境 ...

Compugen's innovative approach targets under-explored immune pathways like PVRIG and IL-18 binding protein. Read why I'm ...

为解决不可切除的局部晚期食管鳞状细胞癌（ESCC）治疗难题，日本国家癌症中心医院东院等机构研究人员开展阿替利珠单抗联合放化疗研究。结果显示该方案有较好疗效与安全性，还找到潜在生物标志物，值得一读。

Pilatus Biosciences 首席执行官兼联合创始人Raven Lin博士表示：“我们很荣幸 PLT012 获得孤儿药资格认定，这是一个里程碑，反映了我们致力于满足肝癌和肝内胆管癌对创新疗法的迫切需求。” Pilatus ...

Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl Pharmaphorum Menu ...

It also offers perks for your immune system. For example, a past study found that treating mice with EGCG increased the number of regulatory T cells in their spleens and lymph nodes. Regulatory T ...

Ukraine or Russia: Whose Side Is Trump On? Nick asks former UK foreign secretary Jeremy Hunt.

The M14TIL trial involved 168 patients with stage 3c to 4 melanoma that was too advanced ... The patient then receives chemotherapy to reduce regulatory T cells that can put a brake on immune ...